Pay in 4 interest-free payments of $6.10 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
10.1042/BST20200270 Summary Keywords GLP-1, immunemetabolic signaling, metabolic disease, neuroendocrine peptides, orphan receptors, peptide therapeutics, polypharmacology Citation Niazi SK (2026) Beyond GLP-1: underexplored peptidereceptor systems as the next frontier in drug discovery
Disclosure The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest
Nonetheless, ePA ensures that, when coverage is allowed, a patients initiation onto therapy is not prevented by paperwork, potentially capturing the drugs value
5 The second phase of insulin secretion consists of a prolonged response, where islet beta-cells synthesise and secrete insulin
